Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for LY294002 (compound)
Most Correlated Studies
- Treated keratinocyte HaCaT cell line overexpressing EGFR, RELA (p65), or HRAS-VAL12D
- Oncogenic PI3K mutations in cancer cells following growth factor deprivation
- Breast epithelial cells that are organized and disorganized in cell culture
- Embryonic EBRTcH3 stem cells with or without MYC(T58A) overexpression treated with LY294002
- CD4+ T cells age and culture condition comparisons treated with rapamycin or LY 294002
Most Relevant Literature
- Synergistic effects of LY294002 and ABT199 on the cell cycle in K562, HL60 and KG1a cells.
- LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑…
- Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells.
- Calcium signaling mediated by aminergic GPCRs is impaired by the PI3K inhibitor LY294002 and its ana…
- Pyrroloquinoline Quinine and LY294002 Changed Cell Cycle and Apoptosis by Regulating PI3K-AKT-GSK3β …
Most Relevant Clinical Trials
- SF1126 for Patients With Relapsed or Refractory Neuroblastoma
- Study the Expression of Annexin A1 and Its Potential Usage as a Prognostic Marker in Oral Cancer
- Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)
- Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
- GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastat…
